日本神経精神医学会

2022.8

Glia-driven neuroinflammation and systemic inflammation in Alzheimer’s disease Invited Reviewed

Hashioka S, Wu Z, Klegeris A

Current Neuropharmacology   2022.7

Effect of Ninjin’yoeito on lipopolysaccharide-induced depressive-like behavior and glial activation in the hippocampus Reviewed

Jaya MA, Hayashida M, Tsuchie K, Jerin SJ, Mamunur R, Miura S, Nagahama M, Otsuki K, Hashioka S, Wake R, Miyaoka T, Tanra AJ, Horiguchi J, Inagaki M

Shimane Journal of Medical Science   2022.6

Improvement in both severe obsessive compulsive disorder and refractory tardive dystonia following electroconvulsive therapy Reviewed

Mihara Y, Otsuki K, Hayashi M, Yamashita S, Nagahama M, Hayashida M, Wake R, Hashioka S, Abe S, Inagaki M

PCN Reports   2022.5

Contribution of "genuine microglia" to Alzheimer's disease pathology Invited Reviewed

Hashioka S, Inoue K, Otsuki K, Hayashida M, Wake R, Kawano N, Takeshita H, Inagaki M

Frontiers in Aging Neuroscience   2022.4

The use of video games, smartphones, and PCs/tablet PCs based on a survey of students' lifestyles: necessary actions Reviewed

Inoue K, Fujita Y, Takeshita H, Hashioka S, Kamura M

Public Health   2022.3

Diversity and regulation of astrocyte neurotoxicity in Alzheimer's disease Invited Reviewed

Hashioka S, McLarnon JG, Klegeris A

Current Alzheimer Research   2021.12

Magnetic resonance spectroscopy in the ventral tegmental area distinguishes responders to suvorexant prior to treatment: A 4-week prospective cohort study Reviewed

Izuhara M, Miura S, Otsuki K, Nagahama M, Hayashida M, Hashioka S, Asou H, Kitagaki H, Inagaki M

Frontiers in Psychiatry   2021.8

Seeking to address issues with COVID-19 vaccines in Japan and to resolve global problems with vaccination programmes Reviewed

Inoue K, Ohira Y, Kawano N, Takeshita H, Hashioka S

International Maritime Health   2021.5

Prompt improvement of difficulty with sleep initiation and waking up in the morning and daytime somnolence by combination therapy of suvorexant and ramelteon in delayed sleep-wake phase disorder Reviewed

Izuhara M, Kawano K, Otsuki K, Hashioka S, Inagaki M

Sleep Medicine   2021.4

Studies support the use of suvorexant for the prevention of delirium Reviewed

Izuhara M, Izuhara HK, Tsuchie K, Araki T, Ito T, Sato K, Miura S, Otsuki K, Nagahama M, Hayashida M, Hashioka S, Wake R, Kimura T, Tsumoto S, Saito Y, Inagaki M

Journal of Clinical Psychiatry   2021.4

Urinary biopyrrins and free immunoglobin light chains are biomarker candidates for screening at-risk mental state in adolescents Reviewed

Wake R, Araki T, Fukushima M, Matsuda H, Inagaki T, Hayashida M, Hashioka S, Horiguchi J, Inagaki M, Miyaoka T, Oh-Nishi A

Early Intervention in Psychiatry   2021.3

Psychosis in a primary hyperparathyroidism patient with mild hypercalcemia Reviewed

Otsuki K, Izuhara M, Miura S, Yamashita S, Nagahama M, Hayashida M, Hashioka S, Miyaoka T, Hotta Y, Shimizu Y, Inagaki M

Medicine (Baltimore)   2021.3

Normalizing hyperactivity of the Gunn rat with bilirubin-induced neurological disorders via ketanserin Reviewed

Miura S, Tsuchie K, Fukushima M, Arauchi R, Tsumori T, Otsuki K, Hayashida M, Hashioka S, Wake R, Miyaoka T, Inagaki M, Oh-Nishi A

Pediatric Research   2021.2

Do Alzheimer’s disease risk gene products actually act in microglia? Reviewed

Hashioka S, Inoue K, Takeshita H, Inagaki M

Frontiers in Aging Neuroscience   2020.12

Drug offenses in the Tokyo metropolitan area: Trends for 2016-2018.

15. Inoue K, Hashioka S, Takeshita H, Fujita Y, Moriwaki S, Murayama Y, Fujita Y, Matsumoto H, Takeichi N, Hoshi M, Noso Y, Okazaki Y

Legal Medicine   2020.11

Real-world preventive effects of suvorexant in intensive care delirium: A retrospective cohort study Reviewed

Izuhara M, Izuhara H, Tsuchie K, Araki T, Ito T, Sato K, Miura S, Otsuki K, Nagahama M, Hayashida M, Hashioka S, Wake R, Kimura T, Tsumoto S, Saito Y, Inagaki M

Journal of Clinical Psychiatry   2020.10

Glia and glial growth factors as new therapeutic targets in neuropsychiatric disorders Invited Reviewed

Hashioka S

CNS & Neurological Disorders - Drug Targets   2020.7

Tailgating (aori-unten): A recent major social issue in Japan Reviewed

Inoue K, Hashioka S, Takeshita H

Medicine, Science and the Law   2020.7

Low serum levels of fibroblast growth factor 2 in Gunn rats: A hyperbilirubinemia animal model of schizophrenic symptoms Reviewed

Hayashida M, Hashioka S, Hayashida K, Miura S, Tsuchie K, Araki T, Izuhara M, Kanayama M, Otsuki K, Nagahama M, Jaya AM, WakeR, Oh-Nishi A, Horiguchi J, Miyaoka T, Inagaki M.

CNS & Neurological Disorders - Drug Targets   2020.7

Risk of an increase in suicide rates associated with economic downturn due to COVID-19 pandemic Reviewed

Inoue K, Hashioka S, Kawano N

Asia-Pacific Journal of Public Health   2020.7

Self-assessed competence in providing care to the severely ill patients among nurses and relatives/caregivers in Kazakhstan Reviewed

Sharapiyeva A, Abzalova R, Inoue K, Hashioka S, Zhetmekova Z

Georgian Medical News   2020.3

Changes in the status of COVID-19 over time necessitate major changes in academics Reviewed

Inoue K, Hashioka S, Inagaki T, Takeshita H, Fujita Y, Ohira Y

International Maritime Health   2020.3

活性化ヒトグリア細胞による神経毒性の研究

2012.4 - 2015.3

基盤研究(C)

活性化グリアによる神経炎症に基づいた精神・神経疾患の病態解明 International coauthorship

2003.4

共同研究 

島根大学法医学講座主催市民公開講座講師

2018.11

出雲第一中学校すこやか委員会

2017.9 - 2022.3

日本生物学的精神医学会　評議員　編集委員

日本神経精神医学会　評議員

日本認知症学会　代議員

日本神経化学会　評議員